Modality
Degrader
MOA
PARPi
Target
TIGIT
Pathway
Ferroptosis
PsANSCLC
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
~Oct 2022
→ ~Jan 2024
NDA/BLA
Apr 2024
→ Sep 2026
NDA/BLACurrent
NCT05336465
2,458 pts·NSCLC
2024-04→2026-09·Active
2,458 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-022d awayPh1 Dose Esc· PsA
2026-09-226mo awayPh3 Readout· NSCLC
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph1 Dose Esc
2026-04-02 · 2d away
PsA
Ph3 Readout
2026-09-22 · 6mo away
NSCLC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05336465 | NDA/BLA | NSCLC | Active | 2458 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |